Late-stage therapies from Fibrogen, Tyme and Novartis need to avoid the same pitfalls as Erytech and Rafael.
A big selloff on a mid-stage stumble seems harsh, but Takeda has problems on the horizon.
The autoimmune target CD40 has yielded few hits despite years of research, but a few companies are keeping the faith.
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
The struggling US biotech receives a $150m windfall from Gilead, a group desperate to make its mark in oncology.